

Updated May 2025

Marta E. Wosińska, Ph.D.

Senior Fellow
Center for Health Policy
The Brookings Institution

1775 Massachusetts Ave NW, Washington DC
mwosinska@brookings.edu

ACADEMIC AND THINK TANK EXPERIENCE

- 7/23-present Senior Fellow, Center on Health Policy, The Brookings Institution
- 4/22-6/23 Visiting Fellow, USC-Brookings Schaeffer Initiative on Health Policy, The Brookings Institution
- 10/19-4/21 Consulting Professor and Deputy Director for Policy, Duke-Margolis Center for Health Policy, Duke University
- 9/07-10/08 Visiting Assistant Professor/Adjunct Professor of Marketing, Columbia Business School
- 7/02-6/08 Assistant Professor of Marketing, Harvard Business School

GOVERNMENT EXPERIENCE

- 4/21-2/22 **Director, Bureau of Economics, Federal Trade Commission**
- Lead a bureau of 100 staff expert in economics of antitrust and consumer protection
 - Successfully implemented significant changes in the bureau's engagement with partners
 - Set a foundation for new rulemaking analysis capability for the agency
- 6/19-10/19 **Economic Advisor, U.S. Senate Finance Committee** (detail)
- Provided guidance on a bipartisan investigation on insulin drug pricing
 - Provided technical assistance on select legislative drug pricing proposals
- 4/16-10/19 **Chief Healthcare Economist, HHS Office of Inspector General**
- Coordinated cross-OIG engagement on drug pricing and opioids
 - Advised on OIG's rules, advisory opinions, audits, and evaluations
- 10/08-4/16 **Director for Economics Staff, FDA Center for Drug Evaluation and Research**
- Directed analyses of the impact of existing and proposed FDA policies on external stakeholders in a broad range of areas including cost of drug development, patient access, post-marketing safety, and generic drug competition

- 9/12-12/12 **Senior Economic Advisor, Food and Drug Administration** (detail)
- Co-authored an influential analysis of drug shortage causes, subsequently featured in the FDA [Drug Shortage Taskforce report](#) (2019) and the [White House report](#) on building resilient supply chains (2021)

PROFESSIONAL SERVICE

- 8/23-7/24 Committee Member, [Ad-hoc Committee on Challenges in Supply, Market Competition, and Regulation of Infant Formula in the United States](#), National Academies of Sciences, Engineering, and Medicine
- 12/20-4/21 Advisory Board Member, [COVID Act Now](#)
- 6/20-4/21 Committee Member, [Ad-hoc Committee on Security of America's Medical Product Supply Chain](#), National Academies of Sciences, Engineering, and Medicine
- 6/20-3/21 Advisory Board Member, [COVID Tracking Project](#)
- 6/20-12/20 Advisor, [COVID Exit Strategy](#)

EDUCATION

- 1996-2002 Ph.D. in Economics, University of California at Berkeley
Fields: Industrial Organization, Economics of Institutions
- 1991-1995 Bachelor of Science, Arizona State University, W.P. Carey School of Business
Major: Economics

GRANTS (SELECTION)

- "Advancing Drug Supply Chain Resilience Policy" (2024-2026) *Uniform Services University* – Co-Principal Investigator
- "Drug Shortages: Addressing Economic Drivers and Policy Barriers" (2024-2026) *Gary and Mary West Health Policy Center*– Principal Investigator
- "Preventing Drug Shortages by Paying for Resilience" (2023) *The Commonwealth Fund* – Principal Investigator
- "A National Network for Critical Technology Assessment: A Pilot" (2022-2023) *National Science Foundation* – Biopharma pilot co-lead
- "Supporting Access to COVID-19 Therapeutics: Preparing for Shortages" (2020-2021) *Arnold Ventures* – Principal Investigator
- "Overcoming the Impediments to Biosimilar Adoption in the U.S.: What Can Be Learned from the Success of Other Countries" (2020-2021) *The Commonwealth Fund* – Principal Investigator
- "Convener and Organizer of Activities and Engagements Focused on the Development of Medical Products and Related Processes, Surveillance, and Policies Relevant to Ongoing Public Health

Activities” (2019-2021) *Food and Drug Administration* – Principal Investigator

“Cooperative Agreement to Support Regulatory Research Related to the 2018 Prescription Drug User Fee Act and the 21st Century Cures Act” (2019-2021) *FDA* – Principal Investigator

WHITE PAPERS

Marta Wosińska (2025) “[The Wild East of Semaglutide](#),” *The Brookings Institution*

Marta Wosińska (2025) “[Will Pharmaceutical Tariffs Achieve Their Goals?](#)” *The Brookings Institution*

Marta Wosińska, Kalah Auchincloss and Ilisa Bernstein (2024) “[FDA Oversight of Drug Manufacturing and Compounding: A Comparison](#),” *The Brookings Institution*

Marta Wosińska (2024) “[Drug Shortages: A Guide to Policy Solutions](#),” *The Brookings Institution*

Marta Wosińska, Rena Conti and Elizabeth Reynolds (2024) “[Workshop Summary: Technology Solutions for Improving the Resilience of Generic Prescription Drug Manufacturing](#),” *The Brookings Institution*

Rena Conti and **Marta Wosińska** (2023) [Critical Technology Assessment for Biopharmaceuticals: Insights from A One-Year Pilot](#), *The Brookings Institution*

Marta Wosińska, Joseph Mattingly II and Rena Conti (2023) “[A Framework for Prioritizing Pharmaceutical Supply Chain Interventions](#),” *Health Affairs Forefronts*

Marta Wosińska and Richard Frank (2023) “[Federal Policies to Address Persistent Drug Shortages](#),” *The Hamilton Project*

Marta Wosińska (2023) “[Drug Shortages and IRA Inflation Rebates: Considerations for CMS](#),” *The Brookings Institution*

Marta Wosińska, Richard Frank (2022) “[Some Drugs That Improve Price Competition Fall through the Cracks of FDA User Fees](#),” *The Brookings Institution*

Rachel Sachs, **Marta Wosińska**, Richard Frank, Loren Adler (2022) “[The FDA Could Do More To Promote Generic Competition: Here’s How](#),” *The Brookings Institution*

Nitzan Arad, Marianne Hamilton-Lopez, Rebecca Ray, Susan Dentzer, Adam Kroetsch, Mark McClellan, **Marta Wosińska** (2021) “[Realizing the Benefits of Biosimilars: What the U.S. Can Learn from Europe](#),” *Duke-Margolis White Paper*

Marta Wosińska, Anna Zavodszky, Morgan Romine, Mark McClellan (2021) “[Promising Practices for Promoting Utilization of COVID-19 Monoclonal Antibody Treatments](#),” *Duke-Margolis White Paper*

Marianne Hamilton-Lopez, Nick Fiore, Nitzan Arad, **Marta Wosińska**, Mark McClellan (2020) “[COVID-19 Monoclonal Antibodies: Paying for Administration and Better Evidence](#),” *Duke-Margolis White Paper*

Morgan Romine, **Marta Wosińska**, Adam Kroetsch, Anna Zavodszky, McClellan, Rob Califf (2020) “[COVID-19 Monoclonal Antibodies: Feasible Mechanisms for Generating Needed Evidence](#),” *Duke-Margolis White Paper*

Marta Wosińska, Anna Zavodszky, Stephen Colvill, Adam Kroetsch, Susan Dentzer (2020) “[Right Patient, Right Time, Right Place: A Critical Challenge of COVID-19 Monoclonal Antibodies](#),” *Duke-Margolis White Paper*

Morgan Romine, Mark McClellan, **Marta Wosińska**, Robert Califf, Hemi Tewarson, Nitzan Arad, Marianne Hamilton-Lopez, Nick Fiore, Anna Zavodszky, Adam Kroetsch (2020) "[COVID-19 Monoclonal Antibodies: Key Issues After Emergency Use Authorization](#)," *Duke-Margolis White Paper*

Kerra Mercon, Nirosha Mahendraratnam, Joy Eckert, Christina Silcox, Morgan Romine, Kathryn Lallinger, Adam Kroetsch, Huzyfa Fazili, **Marta Wosińska**, Mark McClellan (2020) "[A Roadmap for Developing Study Endpoints in Real-World Settings](#)," *Duke-Margolis White Paper*

Monika Schneider, Susan Dentzer, Sarah Sheehan, Karley Whelan, Christina Silcox, Marianne Hamilton Lopez, **Marta Wosińska**, Mark McClellan (2020) "[From Development to Market: Understanding COVID-19 Testing and Its Challenges](#)," *Duke-Margolis White Paper*

Isha Sharma, **Marta Wosińska**, Adam Kroetsch, Haley Sullivan, and Mark McClellan (2020) "[COVID-19 Manufacturing for Monoclonal Antibodies](#)," *Duke-Margolis Issue Brief*

Marta Wosińska (2002) "[Just What the Patient Ordered? Direct-to-Consumer Advertising and the Demand for Pharmaceutical Products](#)," *HBS Marketing Research Paper No. 02-04*

Bronwyn Hall and **Marta Wosińska** (1999) "[The California R&D Tax Credit: Description, History, and Economic Analysis](#)," *California Council on Science and Technology*

COMMENTARY (selection)

Marta Wosińska (2025) "[What will be the impact of drug tariffs: onshoring or shortages?](#)" *The Brookings Institution YouTube Channel*

Marta Wosińska and David Blumenthal (2025) "[How U.S. Tariffs Stand to Impact Prescription Drugs](#)" *Harvard Business Review*

Marta Wosińska (2025) "[Comments on Section 232: The National Security investigation of imports of pharmaceuticals](#)," *The Brookings Institution*

Marta Wosińska and Richard Frank (2024) "[Comments on Senate Finance Committee Draft Legislation to Combat Prescription Drug Shortages](#)," *The Brookings Institution*

Minje Park, Rena Conti, Ozlem Ergun, Erin Fox, Wallace Hopp, **Marta Wosińska** (2023) "[Building Resilience into United States Prescription Drug Supply Chains](#)," *Health Affairs*

Marta Wosińska and Emily Tucker (2023) "[Comments on CMS hospital payment proposal for maintaining a buffer stock of critical medicines](#)," *The Brookings Institution*

Marta Wosińska and Richard Frank (2023) "[Comments on the Request for Information on drug shortages](#)," *The Brookings Institution*

Richard Frank and **Marta Wosińska** (2022) "[The Senate's Plan on Insulin Drugs Is the Wrong Way to Solve the Affordability Problem](#)," *The Hill*

Marta Wosińska and Richard Frank (2022) "[To Prevent Public Health Crises, We Need to Update the Essential Medical Product List](#)," *The Brookings Institution*

David Tawes and **Marta Wosińska** (2016) "[Divorcing Reimbursement from Real-World Prices: Medicare Still Uses 2003 AWP's For Some Drugs](#)," *Health Affairs*

Marta Wosińska, Erin Fox and Valerie Jensen (2015) "[Are Shortages Going Down or Not? Interpreting](#)

[Data from the FDA and the University of Utah Drug Information Service](#),” *Health Affairs*

Marta Wosińska (2013) “[Solving Drug Shortages Requires Incentivizing Reliability, Infrastructure Quality](#),” *Healthcare Finance Bloomberg Brief*

Janet Woodcock and **Marta Wosińska** (2013) “[How to Prevent Drug Shortages Yet Sustain Quality](#),” *Cleanroom Technology* (also published in *Manufacturing Chemist*, 2013)

Marta Wosińska (2012) “[Drug Shortages: Why a Government Stockpile Falls Short](#),” *Health Affairs*

Marta Wosińska (2003) “Advertising to Acquire or Retain?” *DTC Perspectives*

PEER REVIEWED PUBLICATIONS

Rena Conti and **Marta Wosińska** (2025) “[The Economics of Generic Drug Shortages: The Limits of Competition](#)” *Journal of Economic Perspectives*

Nathan Miller, Steven Berry, Fiona Scott Morton, Jonathan Baker, Timothy Bresnahan, Martin Gaynor, Richard Gilbert, George Hay, Ginger Jin, Bruce Kobayashi, Francine Lafontaine, James Levinsohn, Leslie Marx, John Mayo, Aviv Nevo, Ariel Pakes, Nancy Rose, Daniel Rubinfeld, Steven Salop, Marius Schwartz, Katja Seim, Carl Shapiro, Howard Shelanski, David Sibley, Andrew Sweeting, **Marta Wosińska** (2022) “[On the Misuse of Regressions of Price and the HHI in Merger Review](#),” *Journal of Antitrust Enforcement*

Marta Wosińska, David Givens, Yan Lau, Doug Smith, Christopher Taylor and Benjamin Wallace (2021) “[Economics at the FTC: Multi-level Marketing and a Coal Joint Venture](#),” *Review of Industrial Organization*

William Liu and **Marta Wosińska** (2017) “[The Landscape of Contact Manufacturing of Sterile Injectable Drugs: Who is Making What, Where, and for Whom](#),” *Therapeutic Innovation & Regulatory Science*

Kirk Kerr and **Marta Wosińska** (2016) “[Patient Access in Restrictive Risk Management Programs: The Case of iPLEDGE](#),” *Therapeutic Innovation & Regulatory Science*

Janet Woodcock and **Marta Wosińska** (2013) “[Economic and Technological Drivers of Generic Sterile Injectable Drug Shortages](#),” *Clinical Pharmacology and Therapeutics*

Puneet Manchanda, Dick Wittink and others (2005) “[Understanding Firm, Physician and Consumer Choice Behavior in the Pharmaceutical Industry](#),” *Marketing Letters*

Marta Wosińska (2005) “[Direct-to-Consumer Advertising and Drug Therapy Compliance](#),” *Journal of Marketing Research*

Leslie Eldenburg, Benjamin Hermalin, Michael Weisbach, and **Marta Wosińska** (2004) “[Hospital Governance, Performance Objectives, and Organizational Form](#),” *Journal of Corporate Finance*

Marta Wosińska and Robert Huckman (2004) “[Generic Dispensing and Substitution Rates in Mail and Retail Pharmacies](#),” *Health Affairs*

BOOK CHAPTERS

Samuel Kina and **Marta Wosińska** (2009) “[Pharmaceutical Pricing](#)” chapter in the *Handbook of Research in Pricing*, ed. Vithala Rao

TEACHING MATERIALS

Marta Wosińska (2005) “[Marketing Promotions](#),” Harvard Business School Note 506-028

Marta Wosińska and Youngme Moon (2004) “[Propecia®: Making Hair Loss History](#),” HBS Case 505-035

Marta Wosińska (2004) “Propecia®: Making Hair Loss History: Teaching Note,” HBS Case 505-035

CONGRESSIONAL TESTIMONY

Marta Wosińska (2023) [Testimony before the Senate Finance Committee](#) - described authorities needed by CMS to help prevent existing and potential drug shortages

PUBLIC SPEAKING AND PRESENTATIONS

[The role of the U.S. Government in Drug Supply Chain Reliability](#) (4/2025) *The Brookings Institution* – moderator and panelist

[Considering the Safety of the Medicine Supply amid Growing Popularity of Unapproved Versions of GLP-1](#) (4/2025) *American Enterprise Institute* – panelist

[Hatch-Waxman at 40](#) (9/2024) *The Brookings Institution* – panelist

[Solving Decades of Drug Shortages in Oncology: What, Who, and When?](#) (6/2024) *ASCO conference* – panelist

[STAT in DC: Policies to Ease Medicine’s Pain](#) (11/2023) *STAT* – panelist

[How Vital Shortages Happen](#) (8/2023) *MedPage Today* – panelist

[USA: Biosimilar Market Trends, Issues and Outlook](#) (5/2023) *Medicines for Europe* – presenter

[The Shift Toward US Pharmaceutical Manufacturing](#) (3/2023) *Fierce Pharma* – panelist

[Securing Pharmaceutical Supply Chains](#) (3/2023) *The Brookings Institution* – moderator

[Biosimilars in the United States 2023-2027](#) (2/2023) *IQVIA Institute* – panelist

[Reimagining the Pharma Supply Chain](#) (11/2022) *The Hill* - panelist

[Recent Trends in Global Value Chains and Beyond](#) (9/2022) *The Brookings Institution* - panelist

[FDA Approval Pathways 101](#) (6/2022) *Alliance for Health Policy* - moderator

[Building a Resilient Supply Chain](#) (4/2021) *Duke-Margolis Center for Health Policy* - presenter

[Promising Practices for Improving the Use of COVID-19 Monoclonal Antibodies](#) (2/2021) *Duke-Margolis Center for Health Policy* - presenter

[Improving Equity and Access to COVID-19 Monoclonal Antibody](#) (2/2021) *Project ECHO* - presenter

[Scientific and Ethical Considerations for the Inclusion of Pregnant Women in Clinical Trials](#) (2/2021) *Duke-Margolis Center for Health Policy* – moderator

[Allocation of COVID-19 Monoclonal Antibody Therapies and Other Novel Therapeutics](#) (12/2021) *National Academies of Sciences Engineering and Medicine* - presenter

[Improving the Development and Implementation of Shared System REMS](#) (10/2020) *Duke-Margolis*

Center for Health Policy - moderator

[Assessing and Incorporating Intervention Effectiveness in Systems Models of the Opioids Crisis](#)

(10/2020) Duke-Margolis Center for Health Policy - moderator

[Data Sharing to Accelerate Therapeutic Development for Rare Diseases](#) (8/2020) *Duke-Margolis Center for Health Policy - moderator*

[Exploring Policy Options for Establishing Cannabidiol Safety Surveillance](#) (7/2020) *Duke-Margolis Center for Health Policy - moderator*

[Understanding How the Public Perceives and Values Pharmaceutical Quality](#) (2/2020) *Duke-Margolis Center for Health Policy - moderator*

[State of Biomedical Innovation](#) (3/2015) *The Brookings Institution – presenter*

MEDIA INTERVIEWS AND MENTIONS (SELECTION)

Interviews and podcasts featuring my work:

- [How might drug tariffs play out?](#) (4/2025) *BBC World business report* – minutes 11 through 16
- [How do generic drug shortages happen at hospitals?](#) (10/2024) *NPR Planet Money*
- [Race to the Bottom: Hard Bargain](#) (9/2024) *Tradeoffs*
- [Drug Shortages and National Security](#) (3/2023) *NPR All Things Considered*
- [The End of Humira's \\$200 Billion Monopoly](#) (1/2023) *Tradeoffs* podcast

Media mentions in Washington Post, The Atlantic, Politico, New York Times, Bloomberg, Barron's, Financial Times, CNBC, NPR, The Hill, CNN, Nature, STAT, Axios, PBS, Modern Healthcare, US News & Health Report, and many local media outlets

CONSULTING

Serves as an expert witness in pharmaceutical antitrust cases